User s Manual Version 1.0

Similar documents
Supplementary Figure 1: LUMP Leukocytes unmethylabon to infer tumor purity

The 16th KJC Bioinformatics Symposium Integrative analysis identifies potential DNA methylation biomarkers for pan-cancer diagnosis and prognosis

Nature Genetics: doi: /ng Supplementary Figure 1. Workflow of CDR3 sequence assembly from RNA-seq data.

LinkedOmics. A Web-based platform for analyzing cancer-associated multi-dimensional data. Manual. First edition 4 April 2017 Updated on July 3, 2017

Machine-Learning on Prediction of Inherited Genomic Susceptibility for 20 Major Cancers

Supplementary Figures

Exploring TCGA Pan-Cancer Data at the UCSC Cancer Genomics Browser

Session 4 Rebecca Poulos

Nicholas Borcherding, Nicholas L. Bormann, Andrew Voigt, Weizhou Zhang 1-4

TCGA. The Cancer Genome Atlas

Nature Genetics: doi: /ng Supplementary Figure 1. SEER data for male and female cancer incidence from

LncRNA TUSC7 affects malignant tumor prognosis by regulating protein ubiquitination: a genome-wide analysis from 10,237 pancancer

Session 4 Rebecca Poulos

Distinct cellular functional profiles in pan-cancer expression analysis of cancers with alterations in oncogenes c-myc and n-myc

Nature Getetics: doi: /ng.3471

starbase Pan-Cancer Tutorial

LncMAP: Pan-cancer atlas of long noncoding RNA-mediated transcriptional network perturbations

ICLIO National Conference

Genomic and Functional Approaches to Understanding Cancer Aneuploidy

Enterprise Interest Thermo Fisher Scientific / Employee

Expanded View Figures

TCGA-Assembler: Pipeline for TCGA Data Downloading, Assembling, and Processing. (Supplementary Methods)

Comprehensive analyses of tumor immunity: implications for cancer immunotherapy

Package mirlab. R topics documented: June 29, Type Package

File Name: Supplementary Information Description: Supplementary Figures and Supplementary Tables. File Name: Peer Review File Description:

The Cancer Genome Atlas Pan-cancer analysis Katherine A. Hoadley

Supplementary Figure 1: Classification scheme for non-synonymous and nonsense germline MC1R variants. The common variants with previously established

The Cancer Genome Atlas & International Cancer Genome Consortium

Supplementary Tables. Supplementary Figures

OncoPPi Portal A Cancer Protein Interaction Network to Inform Therapeutic Strategies

The Cancer Genome Atlas Clinical Explorer: a web and mobile interface for identifying clinical genomic driver associations

Patnaik SK, et al. MicroRNAs to accurately histotype NSCLC biopsies

Supplementary Figure S1 Expression of mir-181b in EOC (A) Kaplan-Meier

Supplementary. properties of. network types. randomly sampled. subsets (75%

TP53 mutations, expression and interaction networks in human cancers

Promoter methylation of DNA damage repair (DDR) genes in human tumor entities: RBBP8/CtIP is almost exclusively methylated in bladder cancer

microrna PCR System (Exiqon), following the manufacturer s instructions. In brief, 10ng of

SUPPLEMENTARY APPENDIX

Carcinoma renale (I): Posters Review. Elena Verzoni Oncologia Medica 1 SS.Oncologia Genitourinaria Fondazione IRCCS Istituto Nazionale Tumori Milano

RNA SEQUENCING AND DATA ANALYSIS

Cancer of lymph nodes survival rate

4/10/2018. SEER EOD and Summary Stage. Overview KCR 2018 SPRING TRAINING. What is SEER EOD? Ambiguous Terminology General Guidelines

Expert-guided Visual Exploration (EVE) for patient stratification. Hamid Bolouri, Lue-Ping Zhao, Eric C. Holland

Supplemental Information. Integrated Genomic Analysis of the Ubiquitin. Pathway across Cancer Types

RNA SEQUENCING AND DATA ANALYSIS

Elevated RNA Editing Activity Is a Major Contributor to Transcriptomic Diversity in Tumors

Overview of Cancer. Mylene Freires Advanced Nurse Practitioner, Haematology

SUPPLEMENTARY INFORMATION

COMPUTATIONAL OPTIMISATION OF TARGETED DNA SEQUENCING FOR CANCER DETECTION

Ahrim Youn 1,2, Kyung In Kim 2, Raul Rabadan 3,4, Benjamin Tycko 5, Yufeng Shen 3,4,6 and Shuang Wang 1*

Tumor mutational burden and its transition towards the clinic

Transcriptional Profiles from Paired Normal Samples Offer Complementary Information on Cancer Patient Survival -- Evidence from TCGA Pan-Cancer Data

Supplementary Figure 1. Metabolic landscape of cancer discovery pipeline. RNAseq raw counts data of cancer and healthy tissue samples were downloaded

Clustered mutations of oncogenes and tumor suppressors.

Visualization of Human Disorders and Genes Network

Micro-RNA web tools. Introduction. UBio Training Courses. mirnas, target prediction, biology. Gonzalo

Reflex Testing Guidelines for Immunotherapy in Non-Small Cell Lung Cancer

Endogenous retroviral signatures predict immunotherapy response in clear cell renal cell carcinoma

Qué hemos aprendido hasta hoy? What have we learned so far?

a) List of KMTs targeted in the shrna screen. The official symbol, KMT designation,

Nature Immunology: doi: /ni Supplementary Figure 1. RNA-Seq analysis of CD8 + TILs and N-TILs.

Cancer develops as a result of the accumulation of somatic

The transcription levels and prognostic values of seven proteasome alpha subunits in human cancers

Nature Neuroscience: doi: /nn Supplementary Figure 1

The Current Status of Immune Checkpoint Inhibitors: Arvin Yang, MD PhD Oncology Global Clinical Research Bristol-Myers Squibb

Policy. Medical Policy Manual Approved Revised: Do Not Implement until 6/30/2019. Nivolumab

Correlation of gene expression and associated mutation profiles of APOBEC3A, chemosensitivity of cancer cell lines to drug treatment

Only Estrogen receptor positive is not enough to predict the prognosis of breast cancer

Supplementary Materials for

Molecular Testing Updates. Karen Rasmussen, PhD, FACMG Clinical Molecular Genetics Spectrum Medical Group, Pathology Division Portland, Maine

Rare Small Cell Carcinoma in Genitourinary Tract: Experience from E-Da Hospital

Stage 4 liver cancer survival rate

Pan-cancer screen for mutations in non-coding elements with conservation and cancer specificity reveals correlations with expression and survival

Quiz. b. 4 High grade c. 9 Unknown

Transcriptional landscape of human cancers

What you should know before you collect data. BAE 815 (Fall 2017) Dr. Zifei Liu

Poor Outcomes in Head and Neck Non-Melanoma Cutaneous Carcinomas

ASSESSING LONG-TERM BENEFITS OF IMMUNOTHERAPY BASED ON EARLY TUMOR ASSESSMENT DATA

Supplementary Figure 1: Comparison of acgh-based and expression-based CNA analysis of tumors from breast cancer GEMMs.

Biochemistry of Carcinogenesis. Lecture # 35 Alexander N. Koval

Supporting Information

Icd-10 for cancer that spread to the lungs

Supplementary Figure 1: High-throughput profiling of survival after exposure to - radiation. (a) Cells were plated in at least 7 wells in a 384-well

Icd-10 code for metastatic small cell cancer

Understanding Your Pathology Report

Pan-cancer analysis of expressed somatic nucleotide variants in long intergenic non-coding RNA

NATIONAL INSTITUTE FOR HEALTH AND CARE EXCELLENCE. Health Technology Appraisal

THE IMPORTANCE OF COMORBIDITY TO CANCER CARE AND STATISTICS AMERICAN CANCER SOCIETY PRESENTATION COPYRIGHT NOTICE

Expanded View Figures

Oncology 101. Cancer Basics

Cancer Informatics Lecture

Common Questions about Cancer

Acute: Symptoms that start and worsen quickly but do not last over a long period of time.

El contexto molecular de la sobreexpresión de PD-L1 Esther Conde Gallego, MD, PhD

MEDICAL POLICY Gene Expression Profiling for Cancers of Unknown Primary Site

Cumulative metformin use and its impact on survival in gastric cancer patients after INDEX

A Proposed Strategy for Treatment of Superficial Carcinoma. in the Thoracic Esophagus Based on an Analysis. of Lymph Node Metastasis

User Guide. Association analysis. Input

Advances in Brain Tumor Research: Leveraging BIG data for BIG discoveries

Original Article International Cancer Genome Consortium Data Portal a one-stop shop for cancer genomics data

Transcription:

User s Manual Version 1.0 #639 Longmian Avenue, Jiangning District, Nanjing,211198,P.R.China. http://tcoa.cpu.edu.cn/ Contact us at xiaosheng.wang@cpu.edu.cn for technical issue and questions

Catalogue Functions of the "Gene" module...3 The gene expression data include...3 The gene somatic mutation data...5 Functions of the "Cancer" module... 10 Functions of the "Pan-cancer" module... 13 Functions of the "Immuno-Oncology" module... 14 Functions of the "Protein" module... 16 A summary of functions and data display... 18

Functions of the "Gene" module In the "Gene" module, when a user submits the querying of a gene using the gene symbol or Entrez ID, will output the information on expression and somatic mutations of the gene in 33 cancer types. The gene expression data include Gene expression levels in cancers Differential expression comparisons between cancer and normal samples by Student's t test (if the gene expression data in normal samples are available in TCGA)

Expression correlations with other genes by Pearson correlation analysis in cancers Differential expression comparisons by Fisher s exact test between different cancer phenotypes such as TMN Associations of gene expression with survival prognosis by Log-rank test in cancers

The gene somatic mutation data TP53 mutation rates in cancers TP53 variants classification in cancers Comparisons of TP53 mutation rates by Fisher's exact test between different cancer phenotypes such as TMN

Comparisons of TP53 gene expression between TP53-mutated and TP53-widetype cancers by Student s t test Associations of TP53 mutations with survival prognosis by Log-rank test in cancers

Functions of the "MicroRNA" module In the "MicroRNA" module, a user can submit the querying of mirnas using the human mirna symbol. will output the mirna expression-related data in 33 cancer types. These data include: mirna expression levels in cancers Expression correlations with genes by Spearman correlation analysis in cancers Expression correlations with other mirnas by Pearson correlation analysis in cancers

Differential mirna expression comparisons by Student s t test between cancer and normal samples (if the mirna expression data in normal samples are available in TCGA) Differential mirna expression comparisons between different cancer phenotypes such as TMN

Associations of mirna expression with survival prognosis by Log-rank test in cancers

Functions of the "Cancer" module In the "Cancer" module, when a user clicks a cancer type, will output Top 50 most frequently mutated genes in the cancer Up-regulated and down-regulated genes, and up-regulated and down-regulated mirnas in the cancer relative to normal controls. outputs the up-regulated and down-regulated genes or mirnas depending on the threshold input by users. The threshold includes: fold change of expression levels in cancer compared to normal tissue, and adjusted p-value. The adjusted p-values (FDR q-values) The adjusted p- values (FDR q-values) are calculated by the Benjami and Hochberg (BH) method.

This module also outputs important pathways associated with the highly-expressed genes in the cancer type

Functions of the "Pan-cancer" module In the "Pan-cancer" module, outputs the genes consistently up-regulated or down-regulated, pathways significantly up-regulated, and genes whose deregulation is significantly associated with survival prognosis across various cancer types. This module also outputs the genes that are differentially expressed between cancer and normal samples, and between low-advanced and highly-advanced cancers across various cancer types. We refer to early-stage (Stage I-II) or low-grade (Grade I-II) cancers as lowly-advanced cancers, and late-stage (Stage III-IV) or high-grade (Grade III-IV) cancers highly-advanced cancers. A comparison of tumor mutation burden (TMB, defined as the total number of substitutions, regardless of variant type) among different cancer types is also shown in this module (as following picture shows). Figure as following picture shows that skincutaneous melanoma (SKCM) has the highest median TMB, followed by lung adenocarcinoma (LUAD) and lung squamous cell carcinoma (LUSC).

Functions of the "Immuno-Oncology" module In the "Immuno-Oncology" module, provides the querying of 2,877 immunerelated genes about their expression, mutations and associations with survival prognosis in various cancer types. When a user selects a gene, will enter into the gene information interface that is the same as that by the "Gene" module querying of that gene. For example, many users could be interested in the gene PD-L1 whose product plays an important role in cancer immune evasion and is an important target for cancer immunotherapy. shows that PD-L1 has significantly higher expression levels in esophageal carcinoma (ESCA) and kidney chromophobe (KICH), while has significantly lower expression levels in LIHC, LUAD, LUSC and prostate adenocarcinoma (PRAD) compared to their normal tissue (Figure A). Interestingly, elevated expression of PD-L1 is associated with better OS and/or disease free survival (DFS) prognosis in adrenocortical carcinoma (ACC), colon

adenocarinoma (COAD), kidney renal clear cell carcinoma (KIRC), and SKCM, while worse OS and/or DFS prognosis in brain lower-grade glioma (LGG) and PAAD (Figure B).

Functions of the "Protein" module In the "Protein" module, when a user submits the querying of a protein, will output expression data for the protein in 33 cancer types. These data include: Protein expression levels in cancers Protein-gene expression correlation by Spearman correlation analysis in cancers Differential protein expression comparisons by Fisher s exact test between different cancer phenotypes such as TMN

Associations of protein expression with survival prognosis by Log-rank test in cancers

A summary of functions and data display Module Function Visualization Gene MicroRNA Cancer Pan-cancer show mean gene expression values in different cancer types compare gene expression between cancer and normal samples show expression correlation between gene and gene in cancers compare gene expression between different cancer phenotypes (T, N, M, Stage and Grade) compare survival time between gene higher-expression-level and lower-expression-level cancers show gene somatic mutation rates in cancers compare gene somatic mutation rates between different cancer phenotypes (T, N, M, Stage and Grade) classify gene somatic mutations in cancers compare survival time between gene-mutated and gene-widetype cancers compare gene expression between gene-mutated and gene-widetype cancers show mean mirna expression values in different cancer types compare mirna expression between cancer and normal samples show expression correlation between gene and mirna in cancers show expression correlation between mirna and mirna in cancers compare mirna expression between different phenotypes (T, N, M, Stage and Grade) in cancers compare survival time between mirna higher-expression-level and lower-expression-level cancers show mutation rates of the 50 most frequently mutated genes in the cancer type show the up-regulated and down-regulated genes in the cancer type satisfying the threshold given by users show important pathways associated with the highly-expressed genes in the cancer type show the up-regulated and down-regulated mirnas in the cancer type satisfying the threshold given by users show pathways significantly up-regulated in cancers show genes whose upregulation is associated with poor prognosis in cancers show genes whose downregulation is associated with poor prognosis in box plot scatter diagram box plot survival curve box plot pie chart survival curve box plot box plot scatter diagram scatter diagram box plot survival curve survival curve survival

Immuno- Oncology Protein cancers show genes with increased or decreased expression alterations consistently from normal tissue to low-advanced cancers, and from low-advanced cancers to highly-advanced cancers show the cell cycle pathway consistently up-regulated in cancers show genes whose expression levels are significantly higher or lower in cancers than in normal tissue show genes whose expression levels are significantly higher or lower in high-grade cancers than in low-grade cancers show genes whose expression levels are significantly higher or lower in late-stage cancers than in early-stage cancers compare tumor mutation burden among different cancer types query molecular profiles of 2,877 immune-related genes in cancers show mean protein expression levels (normalized) in different cancer types show expression correlation between gene and protein in cancers compare protein expression between different cancer phenotypes (T, N, M, Stage and Grade) compare survival time between protein higher-expression-level and lower-expression-level cancers curve table table table the same as the "Gene" module scatter diagram survival curve Note: T: describes the size of the original (primary) tumor and whether it has invaded nearby tissue. N: describes nearby (regional) lymph nodes that are involved. M: describes distant metastasis (spread of cancer from one part of the body to another). Stage: describes the progression of cancer. Grade: describes the differentiated level of cancer. low-advanced cancers: early-stage (Stage I-II) or low-grade (Grade I-II) cancers. highly-advanced cancers: late-stage (Stage III-IV) or high-grade (Grade III-IV) cancers. tumor mutation burden: the total number of substitutions, regardless of somatic mutation type in tumor.